Risk of Parkinson Disease in Diabetes Mellitus: An Updated Meta-Analysis of Population-Based Cohort Studies

Xuejing Yue, Hehua Li, Haiqing Yan, Ping Zhang, Li Chang, and Tong Li

Abstract: Previous meta-analysis has identified the associations between diabetes mellitus (DM) and the risk of Parkinson disease (PD). However, the results are still debatable. The purpose of this study is to perform an updated meta-analysis to investigate the up-to-date pooling evidence based on published population-based cohort studies and assess the association between DM and the risk of PD.

Electronic database including Pubmed and Embase were searched to identify cohort studies published before October, 2015. Studies were selected if they reported the risk estimates for PD associated with DM. We pooled the adjusted effect estimates using random-effects meta-analysis. Funnel plot, Begg, or Egger test as well as Duval and Tweedie trim-and-fill approach were applied to assess publication bias.

A total of 7 population-based cohort studies, representing 1,761,632 individuals were included in the meta-analysis. The pooled adjusted relative risk (RR) of PD associated with DM was 1.38 (95% CI 1.18–1.62, $P < 0.001$). An effect was consistent in female (RR 1.50 95% CI 1.07–2.11, $P = 0.019$) and in male (RR 1.40, 95% CI 1.17–1.67). The association was similar when stratified by study quality, research region, study design, sample size, published year, diabetes duration, and baseline age. The trim-and-fill approach confirmed the robustness of the result (RR 1.31, 95% CI 1.09–1.57, $P = 0.015$).

Our findings based on population-based cohort studies indicate that diabetes is associated with increased PD risk by about 38%. More large-scale prospective studies are warranted to further clarify this association and its mechanism.

INTRODUCTION

Diabetes mellitus (DM) has been and will continue to be one of the most common chronic diseases globally, which adds a tremendous burden to health care systems. As an age-related neurodegenerative disease, Parkinson disease (PD) shares similar pathophysiological with DM in that both conditions are involved in similar protein misfolding, peripheral and central insulin signaling, and some shared cytotoxic processes. PD and diabetes share similar genetic and environmental factors caused by dysregulation in common pathways. Detrimental environmental exposure, genetic susceptibility, and lifestyle factors may cause mitochondrial and endoplasmic reticulum malfunction, inflammatory response, and metabolic disorder, which contribute to neurodegenerative diseases (such as PD) and/or diabetes. Diabetes can involve multiple systems or organs, such as diabetic neuropathy and Alzheimer disease. Nevertheless, evidence from epidemiological studies has not definitely identified whether preexisting DM has direct relationship with the risk of developing PD.

A previous meta-analysis by Cereda et al. indicated that DM was a risk factor for the future development of PD based on four prospective studies. However, when involved 14 case–control studies, Lu et al. did not find the relationship between DM and risk of PD, which was also reported by Cereda et al. when pooling the results of 5 case–control studies. Due to the interstudy heterogeneity, the seemingly contradictory results add little evidence to the true relationship between DM and risk of developing PD.

Therefore, the purpose of our study is to conduct an updated meta-analysis of the available population-based cohort studies to estimate the impact of preexisting DM on the risk of developing PD.

METHODS

Search Strategy

We searched Pubmed and Embase from inception up to October 2015 with no language limitations using the following search terms: “diabetes mellitus,” “diabetes,” and “Parkinson disease,” and “Parkinson” with the Boolean logical operator AND with studies identified with the terms “Parkinson disease,” Parkinson. The reference lists of all primary selected relevant articles and several previously published reviews and meta-analyses were also scrutinized to identify additional relevant studies on this topic.

Eligibility Criteria

We selected observational cohort studies with prospective or retrospective study design that investigated the association of
DM exposure with PD. The inclusion criteria of this study were
the studies that reported odds ratios (ORs)/relative risks (RRs)/
hazard ratios (HRs) for PD risk in diabetic patients compared
with that in non-diabetic patients, or to provide indirect raw data
to allow for calculation of the risk estimates. Studies had to
define diabetes and PD using self-reported questionnaires or
with the criteria based on the International Classification of
Diseases, 10th revision. Studies were excluded with case–
control study design, if no relevant relative ratio or HR was
reported, or if the participants of the same cohort were published
more than twice. Studies were also excluded for those without
sufficient data for analysis or those without original data such as
comments, letters, reviews, and meta-analyses. Institutional
review board approval and patient consent were not applied
to this meta-analysis of observational studies.

Data Extraction and Quality Assessment

Eligible articles were screened and reviewed independ-
ently by 2 investigators (XJY and HHL), and data were
extracted into a standardized Microsoft Excel spreadsheet.
Any discrepancies were resolved by discussion or by a senior
investigator (TL), until consensus was reached. The following
items were extracted for each study: first author, publication
year, research country, study name, study design, number of
participants, age at baseline, PD and DM diagnostic criteria, risk
estimates for PD, adjusted variables, and analytical method.

The methodological quality of observational cohort studies
was assessed using the Newcastle–Ottawa scale (NOS) by 2
investigators independently (XJY and HHL). According to
this scale, 3 domains were scored concerning selection and
comparability of study cohorts, and ascertainment of the out-
come of interest, with a score range of 0 to 9.

Statistical Analysis

We used the DerSimonian and Laird random effects model
to calculate pooled estimates and corresponding 95% confi-
dence interval (CI). As the prevalence of PD was relatively
rare, ORs were considered approximations of RRs or HRs.
Adjusted risk estimates (ORs/RRs/HRs) reported in studies
were chosen for analysis to account for confounding variables.
The interstudy heterogeneity was tested by the Cochran Q and I²
statistic with an I² value more than 50% representing significant
heterogeneity. We also conducted sensitivity analyses by
excluding 1 study at a time and reanalyzing the remaining
studies to examine whether the results altered substantially by
any individual study. We used the method through visual
inspection of the funnel plot symmetry and Beggs regression
as well as Egger linear regression test to assess the potential of
publication bias. In addition, Duval nonparametric trim-and-
fill procedure was used to assess the possible influence of
publication bias. The statistical analyses were performed
using Stata 12.0 (Stata Corporation, College Station, TX).

FIGURE 1. Flowchart of study selection.
| First Author            | Publication Year | Country       | Study Name                  | Study Design | No of Participants | Age at Baseline, years | PD Diagnostic Criteria                                                                 | DM Diagnostic Criteria | Risk (OR/RR/HR, 95%CI) for PD | Adjusted Variables                                                                 | Analytical Method |
|------------------------|------------------|---------------|----------------------------|--------------|--------------------|-----------------------|----------------------------------------------------------------------------------------|-----------------------|--------------------------------|---------------------------------|---------------------|
| De Pablo-Fernández     | 2014             | Spain         | NEDICES cohort (population based) | Prospective  | 4998               | NR                    | UK PD Society Brain Bank diagnostic criteria                                            | Self-reported questionnaire | OR = 2.07; 95% CI 0.94–4.59; DM > 10 year OR = 3.52; 95% CI 1.22–10.17 | Demographics, cardiovascular risk factors, prevalent chronic diseases, and therapies potentially causing parkinsonism | Multivariate |
| Sun                    | 2012             | China (Taiwan)| NHI cohort (population based) | Retrospective | 1,075,604 (603,416 diabetic patients and 472,188 control) | >20                   | ICD-9: 332 ICD-9: 250 or A code 181                                                   | HR = 1.61 95% CI 1.56–1.66; men: HR = 1.51; 95% CI 1.44–1.57; women: HR = 1.70; 95% CI 1.65–1.77 | Age, sex, geographic area, urbanization status, and comorbidities, including hypertension, hyperlipidemia, and cardiovascular disease | Multivariate |
| Xu                     | 2011             | USA           | NIH-AARP Diet and Health study | Prospective  | 288,662 (21,611 diabetic patients and 267,051 control) | 50–71                 | Neurologist diagnosis Self-administered questionnaire                               | OR = 1.41 95% CI 1.20–1.66 | Age, sex, race, education, smoking, coffee, BMI, and physical activity               | Multivariate |
| Palacios               | 2011             | USA           | CPS-II Nutrition cohort      | Prospective  | 147,096            | ≥18                   | Medical record review Self-administered questionnaire                                   | RR = 1.00 95% CI 0.75–1.34; men: RR = 0.98; 95% CI 0.66–1.46; women: RR = 1.02 95% CI 0.66–1.56 | Age, smoking, alcohol intake, caffeine intake, caloric intake, dairy intake, pesticide exposure, education and physical activity, BMI | Multivariate |
| Driver                 | 2008             | USA           | The Physicians’ Health Study cohort | Prospective  | 21,841             | 40–84                 | Self-reported questionnaires Self-reported questionnaires Men: RR = 1.34 95% CI 1.01–1.77 | RR = 1.04 95% CI 0.74–1.46 | Age, smoking, alcohol use, BMI, physical activity, hypertension, and high serum cholesterol | Multivariate |
| Simon                  | 2007             | USA           | NHS cohort and HPFS cohort   | Prospective  | 171,879            | Women: 30–55; men: 40–75 | Neurologist diagnosis Self-reported history                                           | RR = 1.83 95% CI 1.21–2.76; men: RR = 1.78; 95% CI 1.01–3.12; women: RR = 1.91 95% CI 1.04–3.52 | Age, sex, and Smoking, BMI, physical activity, alcohol, caffeine and energy intake, and comorbidities | Multivariate |
| Hu                     | 2007             | Finland       | The Finland Nationwide cohort | Prospective  | 51,552             | Women: mean 65.8; men: mean 64.3 | Neurologist diagnosis Self-reporting and two nationwide registers.               | RR = 1.52 95% CI 1.21–1.76; men: RR = 1.45; 95% CI 1.16–1.82; women: RR = 1.91 95% CI 1.04–3.52 | Age, sex, smoking, BMI, Multivariate alcohol use, coffee and tea consumption, education, physical activity, systolic blood pressure, and total cholesterol | Multivariate |

AARP = American Association of Retired Persons, BMI = body mass index, CI = confidence interval, DM = diabetes mellitus, HPFS = the Health Professionals Follow-up Study, HR = hazard ratio, ICD = International Classification of Diseases, NR = not reported, NEDICES = the Neurological Disorders in Central Spain, NHI = Taiwan National Health Insurance, NHS = the Nurses Health Study, NIH = the National Institutes of Health, OR = odds ratio, PD = Parkinson disease, RR = relative risk.
We set a $P$ value less than 0.05 indicating statistical significance.

**RESULTS**

Study Characteristics

Figure 1 illustrates the detailed study selection process. In summary, 86 references were initially identified through reading titles or abstracts from 4565 records. After full text review, 79 articles were excluded for multiple reasons (details were provided in Table 2, http://links.lww.com/MD/A937), and only 7 articles were deemed suitable and satisfied the inclusion criteria. Table 1 provides the detailed baseline characteristics of each study that met our inclusion criteria. All 7 studies were cohort studies (6 prospective and 1 retrospective) published between 2007 and 2014 in English peer-reviewed journals. A total of 1,761,632 individuals were included in this study with a median sample size of 147,096 (range, 4998–1,075,604). Four studies were conducted in USA,24,27,29,31 2 in Europe,23,25 and 1 in China (Taiwan).30 Based on NOS, 6 studies were assigned as higher score24,25,27,29–31 and 1 as lower score23 (Table 3). The

![Forest plot](image)

**FIGURE 2.** (A) Forest plot for risk of Parkinson disease in diabetic patients. (B) Forest plot for risk of Parkinson disease in diabetic patients by different genders.
confirmation of PD was based on self-reported questionnaires in 1 study24 and neurological diagnosis based on International Classification of Diseases in 6 studies.2,23,25,27,29–31

Risk of PD in Patients With DM

Pooled analysis of 7 studies showed a significant association between DM and risk of developing PD, RR 1.38 (95% CI 1.18–1.62, P < 0.001, F = 71.2%) compared with nondiabetic patients (Figure 2A). Although substantial statistical heterogeneity was noted in the meta-analysis, almost all of the 7 included studies showed a similar direction of effect, thus demonstrating that some of the heterogeneity mainly attribute to variation in the magnitude of the estimated risk instead of the direction. No evident publication bias was identified when examining for funnel plot asymmetry by Egger test (P = 0.147) or Begg test (P = 0.764). However, due to the limited number of included studies, we should interpret it with caution. We then applied the trim and fill method to conduct the sensitivity analysis and the result indicated 2 missing studies in the funnel plot (Figure 3). However, imputing these 2 hypothesized studies did not largely alter the original pooled estimate (RR 1.31 95% CI 1.09–1.57, P = 0.015). Furthermore, sensitivity analysis by omitting 1 study at a time and recalculating the pooled estimate, the results of that still showed significant association between DM and risk of PD (data no shown) (Figure 4).

Subgroup Analyses

Four studies24,25,27,30 investigating on the prevalence of PD by gender were identified, with a pooled RR of 1.50 (95% CI 1.17–1.87, P < 0.001, F = 45.3%) in male (Figure 2B). The results indicated DM was a significant risk factor of developing PD in both males and females, but no significant difference was observed in PD prevalence between males and females (P = 0.72). Four studies24,25,30,31 investigated whether poor or fair health status (such as stroke, heart disease, cancers, etc.) could influence the combined estimates. The results showed that DM was still associated with significant increased risk of PD (pooled RR 1.45, 95% CI 1.20–1.74) when pooling the estimates from studies that excluded individuals with poor or fair health status (Table 3).

We also assessed the impact of study quality (high quality vs low quality), research country involved (USA vs Europe vs Asia), study design (prospective vs retrospective), sample size

DISCUSSION

In this comprehensive updated meta-analysis based on 7 observational cohort studies analyzing the impact of diabetes on the risk of PD in over 1,761,000 individuals, we noted that, compared to nondiabetic patients, patients with diabetes were associated with a 38% increase in the risk of developing PD, with an increased risk of 50% and 40% in female and in male, respectively. This effect persisted on analysis stratified by study quality, research country, study design, sample size, or published year. The trim and fill method and sensitivity analysis also confirmed the robustness of the association.

Our findings of the current meta-analysis are in line with those of a previous review of observational studies. Based on 4 cohort studies, Cereda et al also concluded that preexisting diabetes was a risk factor for future PD (RR 1.37, 95% CI 1.21–1.55). The mechanisms of the potential roles of diabetes in developing PD are not fully demonstrated. It has been proposed that diabetes might initiate PD through various intrinsic pathways. First, both diabetes and PD involve similar systemic chronic inflammation,37,38 which plays a pivotal role in the occurrence and development of those diseases. Second, oxidative stress, abnormal central dopamine levels, and mitochondrial dysfunction can be noted in both of these 2 age-related chronic diseases.39–42 Furthermore, in vitro studies also show that insulin has some potential role in regulating brain dopaminergic activity.43 Interestingly, other studies proposed that DM is associated with more severe cognitive or postural impairment in PD patients likely through some of the nondisease-specific neurodegeneration mechanisms.44,45 Based on

FIGURE 3. Trimmed and filled funnel plot of diabetes and Parkinson disease.

FIGURE 4. Sensitivity analysis using a random-effect model by omitting 1 study at a time and pooling the other included studies.
these mechanisms, several potential targets for therapeutical interventions in neurodegenerative disorders have been developed. Insulin and glucagon like peptide-1 (GLP-1) (known as an insulinotropic hormone) play a pivotal role in maintaining homeostasis and regulating glucose levels. Besides the intra-cephalic autocrine function, they also contribute to the regulation of neuronal excitability, metabolism, and apoptosis. The blood glucose-lowering effects of GLP-1 are limited by dipeptidyl peptidase 4 which degrades GLP-1. Recently, some drugs have been developed for the treatment of type-2 diabetes, which can also slow the rapid inactivation of GLP-1 through dipeptidyl peptidase 4 inhibition thus exerting a neuroprotective effect. This effect is likely to be a promising approach for the treatment of PD.46

The strengths of this meta-analysis include the comprehensive and reproducible search of the major databases and

TABLE 2. Subgroup Analyses in Subset of Included Studies According to Baseline Characteristics

|                  | RR   | 95% CI       | Heterogeneity, % | P    | No. of Included Studies |
|------------------|------|--------------|------------------|------|------------------------|
| Total            | 1.38 | 1.18–1.62    | 71.2             | <0.001 | 7                      |
| Study quality    |      |              |                  |      |                        |
| NOS score > 6    | 1.36 | 1.15–1.61    | 75.5             | <0.001 | 6                      |
| NOS score ≤ 6    | 2.07 | 0.94–4.59    | –                | –     | 1                      |
| Research region  |      |              |                  |      |                        |
| USA              | 1.22 | 1.02–1.46    | 47.1             | 0.026 | 4                      |
| Europe           | 1.88 | 1.30–2.71    | 0                | 0.001 | 2                      |
| Asia             | 1.61 | 1.56–1.66    | –                | –     | 1                      |
| Study design     |      |              |                  |      |                        |
| Prospective      | 1.31 | 1.10–1.57    | 48.5             | 0.003 | 6                      |
| Retrospective    | 1.61 | 1.56–1.66    | –                | –     | 1                      |
| Sample size      |      |              |                  |      |                        |
| ≥100,000         | 1.30 | 1.05–1.61    | 83.8             | 0.017 | 5                      |
| <100,000         | 1.53 | 1.21–1.94    | 6.4              | <0.001 | 2                      |
| Published year   |      |              |                  |      |                        |
| Before 2010      | 1.34 | 1.01–1.79    | 53.6             | 0.046 | 3                      |
| After 2010       | 1.41 | 1.15–1.72    | 76.8             | 0.001 | 4                      |
| Gender           |      |              |                  |      |                        |
| Female           | 1.50 | 1.07–2.11    | 63.8             | 0.019 | 3                      |
| Male             | 1.40 | 1.17–1.67    | 45.3             | <0.001 | 4                      |

CI = confidence interval, NOS = Newcastle–Ottawa scale, RR = relative risk.

TABLE 3. Subgroup Analyses According to Some of the Selected Baseline Characteristics

|                  | RR   | 95% CI       | Heterogeneity, % | P    | No. of Included Studies |
|------------------|------|--------------|------------------|------|------------------------|
| Overall          |      |              |                  |      |                        |
| All participants | 1.38 | 1.18–1.62    | 71.2             | <0.001 | 7                      |
| Excluding poor health status | 1.59 | 1.50–1.69    | 6.2              | <0.001 | 4                      |
| Diabetes duration, years |      |              |                  |      |                        |
| >10              | 1.28 | 0.95–1.72    | 80.2             | 0.099 | 5                      |
| ≤10              | 2.33 | 1.25–4.34    | 96.4             | 0.008 | 3                      |
| Baseline age, years |      |              |                  |      |                        |
| <40              | 1.61 | 0.98–2.64    | 38.1             | 0.058 | 3                      |
| 41–60            | 2.05 | 1.50–2.25    | 70.9             | <0.001 | 3                      |
| >60              | 1.55 | 1.41–1.70    | 71.9             | <0.001 | 3                      |
| Body mass index  |      |              |                  |      |                        |
| <25 kg/m²        | 1.88 | 1.28–2.77    | –                | –     | 1                      |
| 25 to <30 kg/m²  | 1.14 | 0.75–1.72    | –                | –     | 1                      |
| ≥30 kg/m²        | 0.36 | 0.08–1.59    | –                | –     | 1                      |
| Smoking          |      |              |                  |      |                        |
| Never            | 1.70 | 0.98–2.98    | –                | –     | 1                      |
| Ever or current  | 1.94 | 1.05–5.59    | –                | –     | 1                      |

CI = confidence interval, RR = relative risk.
thoroughly assessment of the effects of diabetes on risk of developing PD based on high quality population-based cohort studies. Compared with the recently published meta-analysis by Lu et al involving case–control studies, this study had a much larger sample size (the largest ever published on this topic) and mainly included high quality population-based cohort studies (6 of 7 with an NOS score of 8 or 9), a sample size of more than 1,761,000 provided the most powerful and comprehensive synthesis of the evidence so far concerning the association between the preexisting DM and risk of PD. Moreover, stratified analyses on the study characteristics were conducted across studies, and generally consistent result was obtained, despite the existence of heterogeneity to some degree. Finally, we formally assessed and rated the study quality or risk of bias for all the included studies using a commonly used scale for cohort studies, and some other approaches, such as trim and fill method, were applied to assess the publication bias.

Several potential limitations should also be addressed. First, there were relatively small number of published studies available for pooling. Therefore, limited subgroup analyses could be conducted to explore possible reasons for heterogeneity for the insufficient power to detect heterogeneity when fewer studies were involved in the analysis. Due to the unavailability of the information in some included studies such as the identification of cases of Parkinsonism or vascular type, not idiopathic PD, sensitivity analyses could not be fully performed and identification bias did exist. Second, as the inherent limitations of observational studies, there was probability of publication bias. Although we scrutinized several major sources to search for all potential relevant studies to minimize publication bias, unpublished gray literature was not included, which might result in the possibility of missing some unpublished data with negative results. However, we applied the trim and filled method to detect this bias and the result was consistent with the original analysis, still showing significant evidence on the relationship between preexisting DM and risk of developing PD. Additionally, differences in the baseline characteristics of each study could also account for the interstudy heterogeneity. The summary results only show variations among the included studies rather than among individual patient. For example, we had no detailed data concerning the DM duration of each patient and the medication history for diabetes. Thus, more detailed meta-analysis could only be conducted if individual patient data could be obtained.

In conclusion, with this meta-analysis, we have attempted to clarify the association between preexisting diabetes and risk of developing PD. We found that compared with nondiabetic individuals, those with diabetes appear to have a significant high incidence of PD. In view of the interstudy heterogeneity, we advocate large-scale prospective studies to elucidate the robustness of the association. Besides, further biological studies should be conducted to demonstrate the potential mechanisms.

ACKNOWLEDGEMENT

The authors thank the statistician, Dr Lixia Liu to double check and revise our statistical analyses.

REFERENCES

1. Ludovico O, Carella M, Biscaglia L, et al. Identification and clinical characterization of adult patients with multigenerational diabetes mellitus. PloS One. 2015;10:e0135855.

2. Glabe CG. Common mechanisms of amyloid oligomer pathogenesis in degenerative disease. Neurobiol Aging. 2006;27:570–575.

3. Santiago JA, Potashkin JA. Shared dysregulated pathways lead to Parkinson’s disease and diabetes. Trends Mol Med. 2013;19:176–186.

4. Arvanitakis Z, Wilson RS, Bienias JL, et al. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol. 2004;61:661–666.

5. Peila R, Rodriguez BL, Launer LJ. Type 2 diabetes, apo gene, and the risk for dementia and related pathologies the hollywood-asia aging study. Diabetes. 2002;51:1256–1262.

6. Association AD. Neurology. AAO. Report and recommendations of the San Antonio conference on diabetic neuropathy. Diabetes Care. 1988;11:592–597.

7. Cereda E, Barichella M, Pedrolli C, et al. Diabetes and risk of Parkinson’s disease: a systematic review and meta-analysis. Diabetes Care. 2011;34:2614–2623.

8. Lu L, Fu DL, Li HQ, et al. Diabetes and risk of Parkinson’s disease: an updated meta-analysis of case-control studies. PloS One. 2014;9:e85781.

9. Becker C, Brobert GP, Johansson S, et al. Diabetes in patients with idiopathic Parkinson’s disease. Diabetes Care. 2008;31:1808–1812.

10. D’Amelio M, Ragone P, Callari G, et al. Diabetes preceding Parkinson’s disease onset. A case–control study. Parkinsonism Relat Disord. 2009;15:660–664.

11. Herishanu YO, Medvedovsky M, Goldsmith JR, et al. A case–control study of Parkinson’s disease in urban population of southern Israel. Can J Neurol Sci. 2001;28:144–147.

12. Ho SC, Woo J, Lee CM. Epidemiologic study of Parkinson’s disease in Hong Kong. Neurology. 1989;39:1314–1314.

13. Kessler IL. Epidemiologic studies of Parkinson’s disease: III. A community-based survey. Am J Epidemiol. 1979;96:242–254.

14. Leibson CL, Maraganore DM, Bower JH, et al. Comorbid conditions associated with Parkinson’s disease: a population-based study. Mov Disord. 2006;21:446–455.

15. Miyake Y, Tanaka K, Fukushima W, et al. Case–control study of Parkinson’s disease in urban population of southern Israel. Can J Neurol Sci. 2010;29:82–86.

16. Morano A, Jimenez-Jimenez FJ, Molina JA, et al. Risk-factors for Parkinson’s disease: case–control study in the province of caceres, Spain. Acta Neurol Scand. 1994;89:164–170.

17. Powers KM, Smith-Weller T, Franklin GM, et al. Diabetes, smoking, and other medical conditions in relation to Parkinson’s disease risk. Parkinsonism Relat Disord. 2006;12:185–189.

18. Rugbjerg K, Friis S, Ritz B, et al. Autoimmune disease and risk for Parkinson disease a population-based case–control study. Neurology. 2009;73:1462–1468.

19. Savica R, Grossardt BR, Ahlholm JE, et al. Metabolic markers or conditions preceding Parkinson’s disease: a case–control study. Mov Disord. 2012;27:974–979.

20. Schernhammer E, Hansen J, Rugbjerg K, et al. Diabetes and the risk of developing Parkinson’s disease in Denmark. Diabetes Care. 2011;34:1102–1108.

21. Sciagliano G, Muscicco M, Solivieri P, et al. Reduced risk factors for vascular disorders in Parkinson disease patients a case–control study. Stroke. 2006;37:1184–1188.

22. Skjie GO, Muller B, Haugarvoll K, et al. Parkinson disease: associated disorders in the Norwegian population based incident ParkWest study. Parkinsonism Relat Disord. 2013;19:53–55.
23. De Pablo-Fernández E, Sierra-Hidalgo F, Sánchez-Ferro A, et al. Diabetes and risk of Parkinson’s disease: evidence from the population-based NEDICES study. Mov Disord. 2014;29:S542.

24. Driver JA, Smith A, Buring JE, et al. Prospective cohort study of type 2 diabetes and the risk of Parkinson’s disease. Diabetes Care. 2008;31:2003–2005.

25. Hu G, Joussilval P, Bidel S, et al. Type 2 diabetes and the risk of Parkinson’s disease. Diabetes Care. 2007;30:842–847.

26. Llorens-Arenas R, Rodriguez-Violante M, Cervantes-Arriaga A, et al. Risk of Parkinson’s disease onset in patients with diabetes, hypertension, dyslipidemia and obesity in Mexican population. Mov Disord. 2015;30:S40–S41.

27. Palacios N, Gao X, McCullough ML, et al. Obesity, diabetes, and risk of Parkinson’s disease. Mov Disord. 2011;26:2253–2259.

28. Palacios N, McCullough M, Jacobs E, et al. Obesity, diabetes and risk of Parkinson disease in a large prospective cohort of men and women. Neuroepidemiology. 2009;33:70–71.

29. Simon KC, Chen H, Schwarzschild M, et al. Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease. Neurology. 2007;69:1688–1695.

30. Sun Y, Chang YH, Chen HF, et al. Risk of Parkinson disease onset in patients with diabetes: a 9-year population-based cohort study with age and sex stratifications. Diabetes Care. 2012;35:1047–1049.

31. Xu Q, Park Y, Huang X, et al. Diabetes and risk of Parkinson’s disease. Diabetes Care. 2011;34:910–915.

32. Quigley J, Thompson J, Halfpenny N, et al. Critical appraisal of non-randomized controlled studies—a review of recommended and commonly used tools. Value Health. 2014;17.

33. Lan KG, Pinheiro J. Combined estimation of treatment effects under a discrete random effects model. Stat Biosci. 2012;4:235–244.

34. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–1558.

35. Egger M, Smith GD, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–634.

36. Peters JL, Sutton AJ, Jones DR, et al. Performance of the trim and fill method in the presence of publication bias and between-study heterogeneity. Stat Med. 2007;26:4544–4562.

37. Pradhan A. Obesity, metabolic syndrome, and type 2 diabetes: inflammatory basis of glucose metabolic disorders. Nutr Rev. 2007;65:S152.

38. Chen H, O’Reilly EJ, Schwarzschild MA, et al. Peripheral inflammatory biomarkers and risk of Parkinson’s disease. Am J Epidemiol. 2008;167:90–95.

39. Sandyk R. The relationship between diabetes mellitus and Parkinson’s disease. Int J Neurosci. 1993;69:125–130.

40. Friederich M, Hansell P, Palm F. Diabetes, oxidative stress, nitric oxide and mitochondria function. Curr Diabetes Rev. 2009;5:120–144.

41. Henchcliffe C, Beal MF. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat Clin Pract Neurol. 2008;4:600–609.

42. Scherrhammer E, Hansen J, Rugbjerg K, et al. Diabetes and the risk of developing Parkinson’s disease in Denmark. Diabetes Care. 2011;34:1102–1108.

43. Craft S, Watson GS. Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol. 2004;3:169–178.

44. Giuntini M, Baldacci F, Del Prete E, et al. Diabetes is associated with postural and cognitive domains in Parkinson’s disease. Results from a single-center study. Parkinsonism Relat Disord. 2014;20:671–672.

45. Bohnen NI, Kotagal V, Müller ML, et al. Diabetes mellitus is independently associated with more severe cognitive impairment in Parkinson disease. Parkinsonism Relat Disord. 2014;20:1394–1398.

46. Nassar NN, Al-Shorbagy MY, Arab IH, et al. Saxagliptin: a novel antiparkinsonian approach. Neuropharmacology. 2015;89:308–317.